<p>Oric Pharmaceuticals（纳斯达克代码：ORIC - 获取免费报告）的股票在周一发布的报告中被 Wedbush 的分析师重申了 “跑赢大盘” 的评级，RTT News 报道。他们目前对该股票的目标价为 20.00 美元。Wedbush 的目标价暗示该公司股价有 49.25% 的潜在上涨空间。</p>
<p>其他股票分析师也对该公司发布了研究报告。Guggenheim 在 9 月 4 日（星期四）发布的报告中开始覆盖 Oric Pharmaceuticals。他们对该股票设定了 “买入” 评级和 18.00 美元的目标价。Zacks Research 在 8 月 12 日（星期二）的研究报告中将 Oric Pharmaceuticals 的评级上调至 “持有”。摩根大通在 8 月 14 日（星期四）的研究报告中将 Oric Pharmaceuticals 的目标价从 20.00 美元下调至 17.00 美元，并对该股票设定了 “增持” 评级。LADENBURG THALM/SH SH 在 7 月 8 日（星期二）的报告中开始覆盖 Oric Pharmaceuticals。他们对该公司发布了 “买入” 评级和 15.00 美元的目标价。最后，Weiss Ratings 在 10 月 8 日（星期三）的报告中重申了对 Oric Pharmaceuticals 股票的 “卖出（d-）” 评级。八位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Oric Pharmaceuticals 的平均评级为 “适度买入”，平均目标价为 17.29 美元。</p>
<p>获取 <strong>Oric Pharmaceuticals</strong> 的提醒：</p>
<p><strong>查看我们对 ORIC 的最新分析</strong></p>
<h2>Oric Pharmaceuticals 股票表现</h2>
<p>ORIC 股票在周一的午盘交易中上涨 0.30 美元，达到 13.40 美元。该公司交易了 1,265,268 股，而其平均交易量为 1,545,989 股。该公司的市值为 13 亿美元，市盈率为-7.09，贝塔值为 1.68。Oric Pharmaceuticals 的 1 年最低价为 3.90 美元，1 年最高价为 14.93 美元。该股票的 50 日简单移动平均线为 11.48 美元，200 日简单移动平均线为 9.40 美元。</p>
<p>Oric Pharmaceuticals（纳斯达克代码：ORIC - 获取免费报告）最近在 8 月 12 日（星期二）发布了其财报。该公司报告本季度每股收益为（0.47 美元），低于分析师一致预期的（0.46 美元），差距为（0.01 美元）。研究分析师平均预计 Oric Pharmaceuticals 在当前年度的每股收益为-2.17 美元。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，首席财务官 Dominic Piscitelli 在 10 月 6 日（星期一）以 14.52 美元的平均价格出售了 11,000 股该公司的股票，总价值为 159,720.00 美元。出售完成后，首席财务官持有该公司 48,317 股，价值约为 701,562.84 美元。此次交易代表其持股比例减少了 18.54%。该交易已在证券交易委员会的法律文件中披露，相关信息可通过此链接访问。此外，首席执行官 Jacob Chacko 在 9 月 22 日（星期一）出售了 125,000 股 Oric Pharmaceuticals 的股票，平均价格为 10.80 美元，总交易额为 1,350,000.00 美元。出售完成后，首席执行官直接持有该公司 656,419 股，价值约为 7,089,325.20 美元。此次交易使其持股比例减少了 16.00%。该交易的披露信息可在此找到。在过去一个季度，内部人士出售了 261,000 股公司股票，价值为 3,024,703 美元。当前 5.55% 的股票由内部人士持有。</p>
<h2>机构投资者对 Oric Pharmaceuticals 的看法</h2>
<p>一些机构投资者最近增加或减少了对该公司的持股。SG Americas Securities LLC 在第三季度购买了 Oric Pharmaceuticals 的新股份，价值约为 216,000 美元。KLP Kapitalforvaltning AS 在第三季度收购了 Oric Pharmaceuticals 的新股份，价值为 85,000 美元。Squarepoint Ops LLC 在第二季度购买了 Oric Pharmaceuticals 的新股份，价值为 1,084,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 Oric Pharmaceuticals 的持股增加了 1,293.0%。Tower Research Capital LLC TRC 现在拥有该公司 11,757 股股票，价值 119,000 美元，此前在该期间内又收购了 10,913 股。最后，Eventide Asset Management LLC 在第二季度收购了 Oric Pharmaceuticals 的新股份，价值为 9,657,000 美元。对冲基金和其他机构投资者目前持有该公司 95.05% 的股票。</p>
<h2>关于 Oric Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>ORIC Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于在美国发现和开发癌症治疗药物。其临床阶段的产品候选包括 ORIC-114，这是一种可穿透大脑的口服生物可用不可逆抑制剂，目前正在进行 1b 期研究，旨在选择性靶向表皮生长因子受体和人类表皮生长因子受体 2，对外显子 20 插入突变具有高效能；ORIC-944，是一种针对前列腺癌的多梳抑制复合体 2 的别构抑制剂，目前正在进行 1b 期研究；以及 ORIC-533，一种口服生物可用的小分子 CD73 抑制剂，目前正在进行 1b 期研究，旨在开发用于化疗和免疫治疗耐药的治疗方案。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Oric Pharmaceuticals</li>
<li>如何计算通货膨胀率</li>
<li>增长选择：三只低成本股票可能翻倍</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>这三只被打压的股票准备反弹吗？</li>
<li>技术股票解析：关于科技你需要知道的</li>
<li>特朗普引发的量子股票反弹是否有持续性？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1JJQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1JJQw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Oric Pharmaceuticals 吗？</h2>
<p>在考虑 Oric Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Oric Pharmaceuticals 并不在名单上。</p>
<p>虽然 Oric Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ORIC

<p>Wedbush 重申了对 ORIC Pharmaceuticals（NASDAQ:ORIC）的 “跑赢大盘” 评级，目标价格为 20.00 美元，暗示潜在上涨空间为 49.25%。其他分析师的评级各不相同，平均目标价格为 17.29 美元。该股票交易价格为 13.40 美元，市值为 13 亿美元。最近的内部交易包括首席财务官 Dominic Piscitelli 和首席执行官 Jacob Chacko 出售股份，表明他们的持股减少。机构投资者持有 95.05% 的股份，反映出对该公司的强烈兴趣</p>

<p>Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report)'s stock had its &#34;outperform&#34; rating restated by analysts at Wedbush in a report issued on Monday,RTT News reports. They presently have a $20.00 price objective on the stock. Wedbush's price target would suggest a potential upside of 49.25% from the company's previous close.</p>
<div class="lb-trans"><p>Oric Pharmaceuticals（纳斯达克代码：ORIC - 获取免费报告）的股票在周一发布的报告中被 Wedbush 的分析师重申了 “跑赢大盘” 的评级，RTT News 报道。他们目前对该股票的目标价为 20.00 美元。Wedbush 的目标价暗示该公司股价有 49.25% 的潜在上涨空间。</p>
</div><p>Other equities analysts have also issued research reports about the company. Guggenheim started coverage on Oric Pharmaceuticals in a report on Thursday, September 4th. They set a &#34;buy&#34; rating and a $18.00 price objective on the stock. Zacks Research upgraded Oric Pharmaceuticals to a &#34;hold&#34; rating in a research note on Tuesday, August 12th. JPMorgan Chase &amp; Co. cut their price target on Oric Pharmaceuticals from $20.00 to $17.00 and set an &#34;overweight&#34; rating on the stock in a research report on Thursday, August 14th. LADENBURG THALM/SH SH assumed coverage on Oric Pharmaceuticals in a report on Tuesday, July 8th. They issued a &#34;buy&#34; rating and a $15.00 price objective for the company. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Oric Pharmaceuticals in a report on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Oric Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and an average target price of $17.29.</p>
<div class="lb-trans"><p>其他股票分析师也对该公司发布了研究报告。Guggenheim 在 9 月 4 日（星期四）发布的报告中开始覆盖 Oric Pharmaceuticals。他们对该股票设定了 “买入” 评级和 18.00 美元的目标价。Zacks Research 在 8 月 12 日（星期二）的研究报告中将 Oric Pharmaceuticals 的评级上调至 “持有”。摩根大通在 8 月 14 日（星期四）的研究报告中将 Oric Pharmaceuticals 的目标价从 20.00 美元下调至 17.00 美元，并对该股票设定了 “增持” 评级。LADENBURG THALM/SH SH 在 7 月 8 日（星期二）的报告中开始覆盖 Oric Pharmaceuticals。他们对该公司发布了 “买入” 评级和 15.00 美元的目标价。最后，Weiss Ratings 在 10 月 8 日（星期三）的报告中重申了对 Oric Pharmaceuticals 股票的 “卖出（d-）” 评级。八位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Oric Pharmaceuticals 的平均评级为 “适度买入”，平均目标价为 17.29 美元。</p>
</div><p>Get <strong>Oric Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Oric Pharmaceuticals</strong> 的提醒：</p>
</div><p><strong>View Our Latest Analysis on ORIC</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ORIC 的最新分析</strong></p>
</div><h2>Oric Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Oric Pharmaceuticals 股票表现</h2>
</div><p>ORIC stock traded up $0.30 during midday trading on Monday, reaching $13.40. 1,265,268 shares of the company were exchanged, compared to its average volume of 1,545,989. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -7.09 and a beta of 1.68. Oric Pharmaceuticals has a 1-year low of $3.90 and a 1-year high of $14.93. The stock's 50-day simple moving average is $11.48 and its 200 day simple moving average is $9.40.</p>
<div class="lb-trans"><p>ORIC 股票在周一的午盘交易中上涨 0.30 美元，达到 13.40 美元。该公司交易了 1,265,268 股，而其平均交易量为 1,545,989 股。该公司的市值为 13 亿美元，市盈率为-7.09，贝塔值为 1.68。Oric Pharmaceuticals 的 1 年最低价为 3.90 美元，1 年最高价为 14.93 美元。该股票的 50 日简单移动平均线为 11.48 美元，200 日简单移动平均线为 9.40 美元。</p>
</div><p>Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.01). On average, research analysts anticipate that Oric Pharmaceuticals will post -2.17 earnings per share for the current year.</p>
<div class="lb-trans"><p>Oric Pharmaceuticals（纳斯达克代码：ORIC - 获取免费报告）最近在 8 月 12 日（星期二）发布了其财报。该公司报告本季度每股收益为（0.47 美元），低于分析师一致预期的（0.46 美元），差距为（0.01 美元）。研究分析师平均预计 Oric Pharmaceuticals 在当前年度的每股收益为-2.17 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CFO Dominic Piscitelli sold 11,000 shares of the firm's stock in a transaction on Monday, October 6th. The shares were sold at an average price of $14.52, for a total value of $159,720.00. Following the completion of the sale, the chief financial officer owned 48,317 shares in the company, valued at approximately $701,562.84. This trade represents a 18.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, CEO Jacob Chacko sold 125,000 shares of Oric Pharmaceuticals stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $10.80, for a total transaction of $1,350,000.00. Following the completion of the sale, the chief executive officer directly owned 656,419 shares in the company, valued at approximately $7,089,325.20. The trade was a 16.00% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 261,000 shares of company stock worth $3,024,703. 5.55% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席财务官 Dominic Piscitelli 在 10 月 6 日（星期一）以 14.52 美元的平均价格出售了 11,000 股该公司的股票，总价值为 159,720.00 美元。出售完成后，首席财务官持有该公司 48,317 股，价值约为 701,562.84 美元。此次交易代表其持股比例减少了 18.54%。该交易已在证券交易委员会的法律文件中披露，相关信息可通过此链接访问。此外，首席执行官 Jacob Chacko 在 9 月 22 日（星期一）出售了 125,000 股 Oric Pharmaceuticals 的股票，平均价格为 10.80 美元，总交易额为 1,350,000.00 美元。出售完成后，首席执行官直接持有该公司 656,419 股，价值约为 7,089,325.20 美元。此次交易使其持股比例减少了 16.00%。该交易的披露信息可在此找到。在过去一个季度，内部人士出售了 261,000 股公司股票，价值为 3,024,703 美元。当前 5.55% 的股票由内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Oric Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Oric Pharmaceuticals 的看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new position in shares of Oric Pharmaceuticals during the 3rd quarter worth approximately $216,000. KLP Kapitalforvaltning AS acquired a new position in Oric Pharmaceuticals during the third quarter worth $85,000. Squarepoint Ops LLC purchased a new position in Oric Pharmaceuticals in the second quarter worth $1,084,000. Tower Research Capital LLC TRC lifted its holdings in Oric Pharmaceuticals by 1,293.0% in the second quarter. Tower Research Capital LLC TRC now owns 11,757 shares of the company's stock valued at $119,000 after acquiring an additional 10,913 shares during the period. Finally, Eventide Asset Management LLC acquired a new stake in Oric Pharmaceuticals in the second quarter valued at $9,657,000. Hedge funds and other institutional investors own 95.05% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者最近增加或减少了对该公司的持股。SG Americas Securities LLC 在第三季度购买了 Oric Pharmaceuticals 的新股份，价值约为 216,000 美元。KLP Kapitalforvaltning AS 在第三季度收购了 Oric Pharmaceuticals 的新股份，价值为 85,000 美元。Squarepoint Ops LLC 在第二季度购买了 Oric Pharmaceuticals 的新股份，价值为 1,084,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 Oric Pharmaceuticals 的持股增加了 1,293.0%。Tower Research Capital LLC TRC 现在拥有该公司 11,757 股股票，价值 119,000 美元，此前在该期间内又收购了 10,913 股。最后，Eventide Asset Management LLC 在第二季度收购了 Oric Pharmaceuticals 的新股份，价值为 9,657,000 美元。对冲基金和其他机构投资者目前持有该公司 95.05% 的股票。</p>
</div><h2>About Oric Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Oric Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.</p>
<div class="lb-trans"><p>ORIC Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于在美国发现和开发癌症治疗药物。其临床阶段的产品候选包括 ORIC-114，这是一种可穿透大脑的口服生物可用不可逆抑制剂，目前正在进行 1b 期研究，旨在选择性靶向表皮生长因子受体和人类表皮生长因子受体 2，对外显子 20 插入突变具有高效能；ORIC-944，是一种针对前列腺癌的多梳抑制复合体 2 的别构抑制剂，目前正在进行 1b 期研究；以及 ORIC-533，一种口服生物可用的小分子 CD73 抑制剂，目前正在进行 1b 期研究，旨在开发用于化疗和免疫治疗耐药的治疗方案。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Oric Pharmaceuticals</li>
<li>How to Calculate Inflation Rate</li>
<li>Growth Picks: 3 Low-Cost Stocks That Could Double in Value</li>
<li>Why Invest in 5G? How to Invest in 5G Stocks</li>
<li>Are These 3 Beaten-Down Stocks Ready to Rebound?</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>Does the Trump-Induced Quantum Stock Rally Have Legs?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Oric Pharmaceuticals</li>
<li>如何计算通货膨胀率</li>
<li>增长选择：三只低成本股票可能翻倍</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>这三只被打压的股票准备反弹吗？</li>
<li>技术股票解析：关于科技你需要知道的</li>
<li>特朗普引发的量子股票反弹是否有持续性？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1JJQw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ORIC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Oric Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Oric Pharmaceuticals 吗？</h2>
</div><p>Before you consider Oric Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Oric Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oric Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Oric Pharmaceuticals 并不在名单上。</p>
</div><p>While Oric Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Oric Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Wedbush 重申对 ORIC Pharmaceuticals（NASDAQ:ORIC）的 “跑赢大盘” 评级